MAGE-A10 SPEAR T-cell therapy: Phase I started

Adaptimmune began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV MAGE A10 TCR in up to 12 patients with an HLA-A*201 or HLA-A*206 allele and tumors expressing MAGEA10....